A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs RG 6061 (Primary)
- Indications Liver cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Roche
- 02 Nov 2017 Planned End Date changed from 15 Oct 2017 to 17 Nov 2017.
- 02 Nov 2017 Planned primary completion date changed from 15 Oct 2017 to 17 Nov 2017.
- 03 Oct 2017 Planned End Date changed from 11 Aug 2017 to 15 Oct 2017.